• Biohaven Pharmaceuticals Reports Third Quarter 2018 Financial And Recent Business Results

    • November 16, 2018
    • Posted By : admin
    • 0 Comment
    Strong and consistent progress continues across multiple drug development platforms with lead calcitonin gene-related peptide (CGRP) receptor antagonist program remaining on timelines for submission of rimegepant new drug application (NDA) in mid-2019- Completed enrollment of 1,466 subjects in the rimegepant Zydis® ODT Phase 3 trial in migraine and 1,895 subjects in the rimegepant long-term safety trial with data expected from both trials by end of 4Q2018- Enrollment of rimegepant Phase 3 prevention of migraine trial expected to commence by end of 4Q2018- First subjects dosed in Phase 1 clinical trial with intranasal formulation of BHV-3500, third-generation small molecule CGRP receptor antagonist, being developed for rapid-onset of action in acute treatment of migraine- Positive results from investigator-initiated proof of concept trial evaluating BHV-0223 in patients with social anxiety disorder and public speaking anxiety- Licensed novel myeloperoxidase inhibitor from AstraZeneca for the treatment of multiple system atrophy (MSA); Biohaven to initiate Phase 3 clinical trial in 2019- Key commercial expertise added to Board of Directors

    NEW HAVEN, Conn., Nov. 14, 2018 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the quarter ended September 30, 2018, and provided a review of recent accomplishments and anticipated milestones.


You Might Also Like

No comments found



error: Content is protected !!